These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25572120)

  • 1. Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.
    Guo Z; Zhang X; Li X; Xie F; Su B; Zhang M; Zhou L
    Oncol Rep; 2015 Mar; 33(3):1519-25. PubMed ID: 25572120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.
    Weng M; Song F; Chen J; Wu J; Qin J; Jin T; Xu J
    Tumour Biol; 2015 Feb; 36(2):959-66. PubMed ID: 25315189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGN5 knockdown sensitizes prostate cancer cells to ionizing radiation.
    Su B; Shi B; Tang Y; Guo Z; Yu X; He X; Li X; Gao X; Zhou L
    Prostate; 2015 Jan; 75(1):33-44. PubMed ID: 25307178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells.
    Zhang XY; Guo ZQ; Ji SQ; Zhang M; Jiang N; Li XS; Zhou LQ
    Asian J Androl; 2012 May; 14(3):487-92. PubMed ID: 22504871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma.
    Zhou X; Yuan B; Yuan W; Wang C; Gao R; Wang J
    Tumour Biol; 2014 Jul; 35(7):6539-47. PubMed ID: 24687550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.
    He J; Liu C; Wang B; Li N; Zuo G; Gao D
    Int J Oncol; 2015 Oct; 47(4):1503-11. PubMed ID: 26315299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-183-3p Inhibits Progression of Human Prostate Cancer by Downregulating High-Mobility Group Nucleosome Binding Domain 5.
    Li Y; He S; Zhan Y; He A; Gong Y; Ji G; Huang C; Peng D; Guan B; Li X; Zhou L
    DNA Cell Biol; 2019 Aug; 38(8):840-848. PubMed ID: 31314587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing HMGN5 suppresses cell growth and promotes chemosensitivity in esophageal squamous cell carcinoma.
    Liu X; Ma W; Yan Y; Wu S
    J Biochem Mol Toxicol; 2017 Dec; 31(12):. PubMed ID: 28914995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of HMGN5 expression by RNA interference induces cell cycle arrest in human lung cancer cells.
    Chen P; Wang XL; Ma ZS; Xu Z; Jia B; Ren J; Hu YX; Zhang QH; Ma TG; Yan BD; Yan QZ; Li YL; Li Z; Yu JY; Gao R; Fan N; Li B; Yang JL
    Asian Pac J Cancer Prev; 2012; 13(7):3223-8. PubMed ID: 22994738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5.
    Wei P; Qiao B; Li Q; Han X; Zhang H; Huo Q; Sun J
    DNA Cell Biol; 2016 Jan; 35(1):33-43. PubMed ID: 26394192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy.
    Yang C; Gao R; Wang J; Yuan W; Wang C; Zhou X
    Tumour Biol; 2014 Jul; 35(7):6357-63. PubMed ID: 24664583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo.
    Gan Y; Tan J; Yang J; Zhou Y; Dai Y; He L; Yao K; Tang Y
    Med Oncol; 2015 Apr; 32(4):136. PubMed ID: 25796505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMGN5 Silencing Suppresses Cell Biological Progression via AKT/MAPK Pathway in Human Glioblastoma Cells.
    Ma Q; Wang X; Wang H; Song W; Wang Q; Wang J
    Biomed Res Int; 2020; 2020():8610271. PubMed ID: 32596388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
    Yao N; Chen Q; Shi W; Tang L; Fu Y
    Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMGN5: a potential oncogene in gliomas.
    Qu J; Yan R; Chen J; Xu T; Zhou J; Wang M; Chen C; Yan Y; Lu Y
    J Neurooncol; 2011 Sep; 104(3):729-36. PubMed ID: 21373965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct properties of human HMGN5 reveal a rapidly evolving but functionally conserved nucleosome binding protein.
    Malicet C; Rochman M; Postnikov Y; Bustin M
    Mol Cell Biol; 2011 Jul; 31(13):2742-55. PubMed ID: 21518955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis.
    Mou J; Huang M; Wang F; Xu X; Xie H; Lu H; Li M; Li Y; Kong W; Chen J; Xiao Y; Chen Y; Wang C; Ren J
    Mol Cancer Res; 2022 Dec; 20(12):1724-1738. PubMed ID: 36066963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research advances in HMGN5 and cancer.
    Shi Z; Tang R; Wu D; Sun X
    Tumour Biol; 2016 Feb; 37(2):1531-9. PubMed ID: 26700674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGN5 promotes invasion and migration of colorectal cancer through activating FGF/FGFR pathway.
    Zhu GJ; Liu F; Xu YG; Zhao CX; Zhao JG; Sun C
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1330-1338. PubMed ID: 33629303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.